Cell-cycle dysregulation and anticancer therapy

被引:286
作者
Stewart, ZA
Westfall, MD
Pietenpol, JA
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Ctr Mol Toxicol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
关键词
D O I
10.1016/S0165-6147(03)00026-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cell-cycle dysregulation is a hallmark of tumor cells. The ability of normal cells to undergo cell-cycle arrest after damage to DNA is crucial for the maintenance of genomic integrity. The biochemical pathways that stop the cell cycle in response to cellular stressors are called checkpoints. Defective checkpoint function results in genetic modifications that contribute to tumorigenesis. The regulation of checkpoint signaling also has important clinical implications because the abrogation of checkpoint function can alter the sensitivity of tumor cells to chemotherapeutics. Here, we provide an overview of the mechanisms that regulate the cell cycle, current anticancer therapies that target checkpoint signaling pathways, and strategies for the development of novel chemotherapeutic agents.
引用
收藏
页码:139 / 145
页数:7
相关论文
共 73 条
[11]   Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound [J].
Bykov, VJN ;
Issaeva, N ;
Shilov, A ;
Hultcrantz, M ;
Pugacheva, E ;
Chumakov, P ;
Bergman, J ;
Wiman, KG ;
Selivanova, G .
NATURE MEDICINE, 2002, 8 (03) :282-288
[12]   Mutations of mitotic checkpoint genes in human cancers [J].
Cahill, DP ;
Lengauer, C ;
Yu, J ;
Riggins, GJ ;
Willson, JKV ;
Markowitz, SD ;
Kinzler, KW ;
Vogelstein, B .
NATURE, 1998, 392 (6673) :300-303
[13]   Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer [J].
Catzavelos, C ;
Bhatacharya, N ;
Ung, YC ;
Wilson, JA ;
Roncari, L ;
Sandhu, C ;
Shaw, P ;
Yeger, H ;
MoravaProtzner, I ;
Kapusta, L ;
Franssen, E ;
Pritchard, KI ;
Slingerland, JM .
NATURE MEDICINE, 1997, 3 (02) :227-230
[14]   14-3-3σ is required to prevent mitotic catastrophe after DNA damage [J].
Chan, TA ;
Hermeking, H ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
NATURE, 1999, 401 (6753) :616-620
[15]   Selected novel anticancer treatments targeting cell signaling proteins [J].
Elsayed, YA ;
Sausville, EA .
ONCOLOGIST, 2001, 6 (06) :517-537
[16]   p53 Regulation of G2 checkpoint is retinoblastoma protein dependent [J].
Flatt, PM ;
Tang, LJ ;
Scatena, CD ;
Szak, ST ;
Pietenpol, JA .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (12) :4210-4223
[17]   Functions of the MDM2 oncoprotein [J].
Freedman, DA ;
Wu, L ;
Levine, AJ .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :96-107
[18]   The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01 [J].
Graves, PR ;
Yu, LJ ;
Schwarz, JK ;
Gales, J ;
Sausville, EA ;
O'Connor, PM ;
Piwnica-Worms, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (08) :5600-5605
[19]   14-3-3σ is a p53-regulated inhibitor of G2/M progression [J].
Hermeking, H ;
Lengauer, C ;
Polyak, K ;
He, TC ;
Zhang, L ;
Thiagalingam, S ;
Kinzler, KW ;
Vogelstein, B .
MOLECULAR CELL, 1997, 1 (01) :3-11
[20]   Functional discovery via a compendium of expression profiles [J].
Hughes, TR ;
Marton, MJ ;
Jones, AR ;
Roberts, CJ ;
Stoughton, R ;
Armour, CD ;
Bennett, HA ;
Coffey, E ;
Dai, HY ;
He, YDD ;
Kidd, MJ ;
King, AM ;
Meyer, MR ;
Slade, D ;
Lum, PY ;
Stepaniants, SB ;
Shoemaker, DD ;
Gachotte, D ;
Chakraburtty, K ;
Simon, J ;
Bard, M ;
Friend, SH .
CELL, 2000, 102 (01) :109-126